ICU Medical upgraded to Buy from Hold at Jefferies

Jefferies upgraded ICU Medical (ICUI) to Buy from Hold with an unchanged price target of $200. The firm continues to like ICU’s core infusion pump marker, which it says is supported by a “healthy” utilization environment with share gain and margin expansion opportunities. The pullback in the shares appears to bake in tariff risk, and the current valuation based “appears compelling relative to the company’s growth profile at twice peers,” the analyst tells investors in a research note.